JAK inhibitors vs. standard care for rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study compares two treatment approaches for rheumatoid arthritis (RA): newer drugs called JAK inhibitors and traditional treatments. It aims to see which is more effective at reducing symptoms and improving daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rheumatoid arthritis (RA) by a doctor using standard criteria.
- You are between 18 and 60 years old.
- You do not have other autoimmune diseases like lupus or psoriatic arthritis.
- You have no current infections, cancer, or chronic conditions like kidney disease or anemia unrelated to RA.
- Your RA is not in remission (it is active).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
This Phase 4 study tests whether a JAK inhibitor (baricitinib) can improve how RA-related bone erosion heals. You might be eligible if you have rheumatoid arthritis that is still active despite methotrexate treatment, and you meet the specific safety and medication history rules.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
This trial studies advanced medicines for rheumatoid arthritis (RA) in people whose RA is still active despite several standard treatments. It may help by testing whether a different advanced option can better control symptoms and joint inflammation.
This study follows patients with inflammatory arthritis (rheumatoid arthritis or spondyloarthritis) to learn more about how well biologic or targeted therapies work. If you have tried standard treatments without enough relief, this may help researchers improve future care.
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.